Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 1999

View Archived Issues

New topical ciclosporin formulation effective for site-specific immunosuppression

Intercardia restructures relationship with Interneuron, changes name to Incara

Cantab's therapeutic vaccine for genital warts enters phase II trials

New Amgen compounds for disorders mediated by TNF-alpha, collagenase and/or stromelysin

Wide series of factor Xa inhibitors specifically claimed by DuPont

Effective hypoglycemic agents arise from U.S.-French collaborative effort

Takeda patents inhibitors of ICAM-1/ELAM-1 expression for immune, autoimmune disorders

Pharmacia & Upjohn's new oxazolidinones exhibit weak or no MAO inhibition

Roche claims another series acting as OFQ receptor antagonists

Zambon presents phthalazines useful for Rx of inflammatory/allergic disorders

Peptoids with antibacterial activity designed by Chiron and collaborators

Hodgkin's lymphoma cell discovered by international team

Ilex acquires Convergence and expands anticancer pipeline

Short-course nevirapine effective in reducing mother-to-infant transmission of HIV

Everninomicin antibiotic effective in patients with penicillin-resistant pneumonia

E-5564 and E-5531: novel endotoxin antagonists discussed at Birmingham meeting

Sibia licenses transcription-based assay technology to Pharmacia & Upjohn

ProNeura completes proof-of-concept studies for sustained drug delivery system

Potential drug interactions with ZD-0870 evaluated in humans

Pharmacokinetics of linezolid not affected by liver disease

Behavioral effects of new third-generation SERM and known nonsteroidal ER ligands

In vitro antibacterial activity of DK-35C discussed at recent congress

Rotavirus vaccine temporarily suspended due to reports of intussusception

New steroids with potential as androgen receptor-mediated imaging agents

Chilean researchers investigate potential new treatments for Chagas' disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...